Shire Blocks Actavis' Generic Lialda Until 2020

Law360, New York (May 9, 2013, 4:38 PM EDT) -- A Florida federal judge on Thursday blocked Actavis Inc.'s bid to launch a generic version of Shire PLC's inflammatory bowel disease treatment Lialda, ruling that Shire's patent for the drug was both valid and infringed.

Following a five-day bench trial last month, U.S. District Judge Donald M. Middlebrooks said Shire's branded formula of time-released mesalazine was validly patented as U.S. Patent Number 6,773,720, which he said Actavis had infringed when it applied for regulatory approval of a no-name version of Lialda.

The ruling means Actavis will...
To view the full article, register now.